FDAnews
www.fdanews.com/articles/159788-fda-clears-ranbaxy-us-subsidiary-of-cgmp-violations

FDA Clears Ranbaxy U.S. Subsidiary of cGMP Violations

October 25, 2013
Ranbaxy enjoyed some recent good news when its U.S. subsidiary resolved FDA current good manufacturing practice (cGMP) violations resulting from a 2012 inspection. The resolution came in the form of an establishment inspection report (EIR) to Ohm Laboratories, Ranbaxy said Oct. 10. The EIR is a boon for Ohm, which supplies a majority of the Indian drugmaker’s prescription and OTC products in the U.S. Ranbaxy’s Indian facilities remain under an FDA import alert.
Washington Drug Letter